Corbus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRBP) $6.69 +1.84 (+37.94%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$4.76▼$6.6950-Day Range$3.16▼$6.8052-Week Range$2.11▼$13.17Volume46,973 shsAverage Volume144,066 shsMarket Capitalization$29.57 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Corbus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.8% Upside$12.50 Price TargetShort InterestBearish1.29% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.63Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.00) to ($6.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector567th out of 949 stocksPharmaceutical Preparations Industry262nd out of 435 stocks 3.5 Analyst's Opinion Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Corbus Pharmaceuticals has a forecasted upside of 86.8% from its current price of $6.69.Amount of Analyst CoverageCorbus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.29% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 3.28%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Corbus Pharmaceuticals is -0.65. Previous Next 2.0 News and Social Media Coverage News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.73% of the stock of Corbus Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($11.00) to ($6.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 95.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More CRBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRBP Stock News HeadlinesNovember 29, 2023 | uk.investing.comCorbus Pharmaceuticals Holding (0SZI)November 23, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Corbus Pharmaceuticals (NASDAQ:CRBP)December 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 7, 2023 | msn.comCorbus Pharmaceuticals GAAP EPS of -$2.27 misses by $0.21November 7, 2023 | finance.yahoo.comCorbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 7, 2023 | finance.yahoo.comCorbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 MillionNovember 2, 2023 | finance.yahoo.comCorbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingNovember 2, 2023 | finance.yahoo.comCorbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!October 17, 2023 | finance.yahoo.comCorbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023October 16, 2023 | finance.yahoo.comCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701October 3, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023September 27, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingSeptember 19, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 13, 2023 | thestreet.comCorbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status DesignationSeptember 10, 2023 | uk.finance.yahoo.comCRBP - Corbus Pharmaceuticals Holdings, Inc.August 9, 2023 | msn.comOppenheimer Reiterates Corbus Pharmaceuticals Holdings (CRBP) Outperform RecommendationAugust 8, 2023 | finance.yahoo.comCorbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 31, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceJune 26, 2023 | seekingalpha.comCorbus Pharmaceuticals to join Russell Microcap indexJune 26, 2023 | finance.yahoo.comCorbus Pharmaceuticals Set to Join Russell Microcap® IndexMay 31, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare ConferenceMay 23, 2023 | fool.comCorbus Pharmaceuticals (NASDAQ: CRBP)May 9, 2023 | msn.comRecap: Corbus Pharmaceuticals Q1 EarningsMay 8, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitorsMay 5, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms marketMay 4, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gainsSee More Headlines Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees33Year Founded2009Price Target and Rating Average Stock Price Target$12.50 High Stock Price Target$22.00 Low Stock Price Target$3.00 Potential Upside/Downside+131.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-320.24% Return on Assets-95.90% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$880,000.00 Price / Sales27.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book77.14Miscellaneous Outstanding Shares4,420,000Free Float4,123,000Market Cap$23.87 million OptionableOptionable Beta2.33 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Yuval Cohen Ph.D. (Age 48)CEO & Director Comp: $890.67kMr. Sean F. Moran CPA (Age 65)M.B.A., Chief Financial Officer Comp: $579.05kDr. Rachael Brake Ph.D. (Age 51)Chief Scientific Officer Comp: $552.22kTed JenkinsSenior Director of Investor Relations & Corporate CommunicationsMs. Lindsey SmithHead of Corporate Communications & Patient AdvocacyMs. Christina BertschHead of Human ResourcesMore ExecutivesKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYDURECTNASDAQ:DRRXCocrystal PharmaNASDAQ:COCPEquilliumNASDAQ:EQIndaptus TherapeuticsNASDAQ:INDPView All Competitors CRBP Stock Analysis - Frequently Asked Questions Should I buy or sell Corbus Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks. What is Corbus Pharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $22.00. On average, they anticipate the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 86.8% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts. How have CRBP shares performed in 2023? Corbus Pharmaceuticals' stock was trading at $0.1105 at the start of the year. Since then, CRBP stock has increased by 5,954.3% and is now trading at $6.69. View the best growth stocks for 2023 here. When is Corbus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our CRBP earnings forecast. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.06) by $0.21. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB). Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CRBP) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.